Previous 10 | Next 10 |
Gainers: Myomo (NYSEMKT: MYO ) +48% . More news on: Myomo, Inc., Enphase Energy, Inc., Altisource Asset Management Corporation, Stocks on the move, , Read more ...
Gene therapy developer Genprex ( GNPX -16.8% ) slumps on increased volume in early trade in reaction to its direct offering of 5M common shares to institutional investors at $3.50 per share yielding gross proceeds of ~$17.5M. More news on: Genprex, Inc., Healthcare stocks news, Stocks ...
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform,...
Gainers : BioXcel Therapeutics (NASDAQ: BTAI ) +58% . More news on: BioXcel Therapeutics, Inc., Genprex, Inc., ImmunoGen, Inc., Stocks on the move, , Read more ...
BioXcel Therapeutics (NASDAQ: BTAI ) +67% . More news on: BioXcel Therapeutics, Inc., Canopy Growth Corporation, Blink Charging Co., Stocks on the move, , Read more ...
Gainers: CounterPath (NASDAQ: CPAH ) +32% . More news on: CounterPath Corporation, Genprex, Inc., Happiness Biotech Group Limited, Stocks on the move, , Read more ...
Gainers : Rexahn Pharmaceuticals (NASDAQ: REXN ) +85% . More news on: Rexahn Pharmaceuticals, Inc., Sprint Corporation, Genprex, Inc., Stocks on the move, , Read more ...
Nano cap Genprex ( GNPX +28.6% ) is up on more than double normal volume in reaction to its agreement with the University of Pittsburgh for exclusive rights to a gene therapy for the potential cure of type 1 and type 2 diabetes. More news on: Genprex, Inc., Healthcare stocks news, Stoc...
Sprint (NYSE: S ) +74% after judge approves T-Mobile merger . More news on: Sprint Corporation, Rexahn Pharmaceuticals, Inc., ZK International Group Co., Ltd., Stocks on the move, Read more ...
February 11, 2020 Palm Beach, FL –February 11, 2020 – The global diabetes drugs market size was valued at USD $48,753.1 Million in 2018, is projected to reach USD 78,261.7 Million by the end of 2026, exhibiting a CAGR of 6.1%, according to industry reports. Rise in obesi...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...